Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors
- PMID: 17177200
- DOI: 10.1002/cncr.22440
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors
Abstract
Background: Postchemotherapy surgery is an essential component in the management of patients with metastatic germ cell tumors (GCT). The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT.
Methods: By analyzing the institutional prospective surgical database from 1989 to 2004, 71 patients were identified who underwent RPLND after multiple chemotherapy regimens. Clinicopathologic and treatment trends were characterized, and predictors of disease-specific survival (DSS) were evaluated.
Results: The histologic findings at RPLND were fibrosis in 36 men (51%), GCT in 20 men (28%), and teratoma in 15 men (21%). Patients who underwent RPLND from 1989 to 1998 (n = 47), compared with patients who underwent RPLND from 1999 to 2004 (n = 24) were more likely to have GCT (36% vs 13%; P = .04). Patients who received taxane-containing chemotherapy regimens as salvage therapy had lower rates of GCT at RPLND (14% vs 42%; P = .01), higher rates of fibrosis (63% vs 39%; P = .04), and similar rates of teratoma (31% vs 33%; P = .9). The 5- and 10-year DSS rates were 74% (95% confidence interval [95% CI], 62-86%) and 70% (95% CI, 56-84%), respectively. Five-year DSS based on worst histology of RPLND and extraretroperitoneal specimens was 87% (95% CI, 75-99%) for fibrosis, 87% for teratoma (95% CI, 63-100%), and 47% for GCT (95% CI, 23-71%; P = .004). On multivariable analysis, retroperitoneal mass > or = 5 cm and GCT were predictors of worse DSS (P = .03 and P = .005, respectively).
Conclusions: Taxane-based salvage chemotherapeutic regimens appear to have decreased the rate of GCT at RPLND. The current data support RPLND in select patients after salvage chemotherapy, because a considerable proportion has teratoma or GCT, and the 10-year DSS rate after resection is 70%.
(c) 2007 American Cancer Society.
Similar articles
-
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.J Clin Oncol. 2007 Mar 20;25(9):1033-7. doi: 10.1200/JCO.2005.05.4791. Epub 2007 Jan 29. J Clin Oncol. 2007. PMID: 17261854
-
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.J Clin Oncol. 2007 Oct 1;25(28):4365-9. doi: 10.1200/JCO.2007.11.2078. J Clin Oncol. 2007. PMID: 17906201
-
Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394
-
Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.Eur Urol. 2008 Feb;53(2):260-72. doi: 10.1016/j.eururo.2007.10.033. Epub 2007 Oct 31. Eur Urol. 2008. PMID: 18045770 Review.
-
Retroperitoneal lymph node dissection after chemotherapy.BJU Int. 2009 Nov;104(9 Pt B):1404-12. doi: 10.1111/j.1464-410X.2009.08867.x. BJU Int. 2009. PMID: 19840021 Review.
Cited by
-
Retroperitoneal lymph node dissection for metastatic germ cell tumours.Ann R Coll Surg Engl. 2011 May;93(4):301-5. doi: 10.1308/003588411X571098. Ann R Coll Surg Engl. 2011. PMID: 21944797 Free PMC article.
-
Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.Urology. 2018 Aug;118:114-118. doi: 10.1016/j.urology.2018.04.009. Epub 2018 Apr 25. Urology. 2018. PMID: 29704586 Free PMC article.
-
Drug development for noncastrate prostate cancer in a changed therapeutic landscape.Nat Rev Clin Oncol. 2018 Mar;15(3):168-182. doi: 10.1038/nrclinonc.2017.160. Epub 2017 Oct 17. Nat Rev Clin Oncol. 2018. PMID: 29039422 Free PMC article. Review.
-
Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Curr Oncol Rep. 2024 Apr;26(4):318-335. doi: 10.1007/s11912-024-01511-y. Epub 2024 Mar 2. Curr Oncol Rep. 2024. PMID: 38430323 Free PMC article. Review.
-
Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences.Nephrourol Mon. 2015 Sep 16;7(5):e27343. doi: 10.5812/numonthly.27343. eCollection 2015 Sep. Nephrourol Mon. 2015. PMID: 26539420 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical